#VisualAbstract: Enfortumab Vedotin and Pembrolizumab Reduces Mortality in Metastatic Urothelial Carcinoma
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. ...
Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. ...
1. The objective response rate was 28% with a complete response of 5.6% and a partial response of 23%. 2. ...
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.